AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
This acquisition enables MTD to open new, strategic markets
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Executes the first project for developing and manufacturing a novel anticancer mAb
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Subscribe To Our Newsletter & Stay Updated